Does UPADACITINIB Cause Mobility decreased? 773 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 773 reports of Mobility decreased have been filed in association with UPADACITINIB (Rinvoq). This represents 1.2% of all adverse event reports for UPADACITINIB.
773
Reports of Mobility decreased with UPADACITINIB
1.2%
of all UPADACITINIB reports
87
Deaths
283
Hospitalizations
How Dangerous Is Mobility decreased From UPADACITINIB?
Of the 773 reports, 87 (11.3%) resulted in death, 283 (36.6%) required hospitalization, and 87 (11.3%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 773 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which UPADACITINIB Alternatives Have Lower Mobility decreased Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL